Tempus Unveils New Mobile App Following Massive Fundraising Push

Eric Lefkofsky is one of the most established Chicago-based entrepreneurs currently working in the tech industry. With a background in data analytics and compilation, Lefkofsky had an array of areas that he could push his career toward into the future. With that being said, Lefkofsky has been focused on developing the company that Eric Lefkofsky co-founded, Tempus. Tempus is a Chicago startup that aims to bring data collection and analysis of clinical and molecular into the modern era. The goal of Tempus is simple: to provide the tools that doctors need in order to promote better cancer treatment. Lefkofsky and Tempus recently made their way through a stunning $100 million cycle of Series E funding and with momentum on their side, Lefkofsky is happy to announce the release of a Tempus mobile application.

The mobile application that Tempus will be releasing on both Google Play and the App Store is titled Tempus Labs. The application was put into rotation for stress testing with doctors all through the nation. Now, Tempus Labs will be available for use to physicians who opt to order one of the special TEMPUS CAP/CLIA validated assays which include the xT, xO, or the xE.

The Tempus Labs application will allow physicians to immediately access the clinical history and therapy options for their specific patients. The app was developed with heavy input from physicians all throughout the country and Tempus is seeking to make it a difference maker in the healthcare field. Specifically, the goal of the application is to help with Tempus’s continual push toward bringing healthcare as it stands today into the modern world of advanced technology. By utilizing this technology, the team at Tempus believes that they can make a difference in the lives of countless patients undergoing treatment.

Tempus has been surging for the better part of the past two years as Eric Lefkofsky and his team of professionals continue to hone in on their work in oncology. The Tempus Labs application represents another step forward and a chance for Tempus to expand their reach in a way that matters to doctors and patients alike.

For details:  www.britannica.com/biography/Eric-Lefkofsky